Answers are grounded in this paper and cite their sources.
Herpes simplex virus type 2 (HSV-2) establishes lifelong infection through cycles of epithelial replication, neuronal latency, and periodic reactivation. While robust immune responses do not lead to viral clearance, they do play a central role in limiting the tissue impact of ongoing virus shedding that is part of the natural history of HSV-2. In sensory ganglia, CD8 + T cells suppress viral reactivation through non-cytolytic mechanisms, allowing persistence of latent viral genomes. At mucosal sites, tissue-resident memory T cells (TRM cells) provide rapid, localized responses that help contain viral spread. However, HSV-2 replication in epithelial tissues occurs rapidly and can outpace the activation and recruitment of circulating immune cells, creating a temporal mismatch that permits viral shedding despite immune surveillance. These findings suggest that HSV-2 persistence confers a kinetic and spatial advantage over immune responses, underscoring the need for next-generation vaccines and therapeutic strategies that enhance tissue-localized, early immune control and target latent viral reservoirs. This review examines HSV-2 infection as a continuous immunological process across epithelial and neuronal compartments and discusses its implications for vaccine development and therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Verdipanah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: